Compare Adaptive Biotechnologies Corp (ADPT) vs Chewy Inc (CHWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Chewy Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.03 (market cap $4.04B), while Chewy Inc trades at $22.11 (market cap $9.20B). The key difference: Chewy Inc is far larger — about 2.3× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Chewy Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | CHWY | |
|---|---|---|
Market Cap | $4.04B | $9.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $42.33 |
52-Week Low | $12.30 | $17.51 |
Enterprise Value | $4.10B | $9.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Chewy (CHWY) trades at $22.16, down 1.9% on the day, with a bearish technical signal from moving averages but neutral oscillators. Revenue grew to $11.86B in 2025, with net income surging to $392.74M, though the net margin remains thin at 1.99%. Recent news highlights insider sales and institutional position changes, while analyst consensus remains strongly bullish with an 81.58% buy rating and a $33.82 price target.
The outlook is mixed: strong revenue growth and high ROE support upside potential, but thin margins, competitive pressures, and recent insider selling pose risks. Earnings beats in recent quarters provide momentum, yet the stock faces volatility near key support at $22. Investors should weigh robust analyst optimism against execution challenges in the pet care market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Chewy Inc
Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →
